Spots Global Cancer Trial Database for hematologic diseases
Every month we try and update this database with for hematologic diseases cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT) | NCT00231309 | Hematologic Dis... Hematologic Mal... | Granulocyte Col... | - 55 Years | Emory University | |
| Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors | NCT05755854 | Hematologic Dis... | allogeneic γ9δ2... Fludarabine Cyclophosphamid... Zoredronic acid | 12 Years - 65 Years | Anhui Provincial Hospital | |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | NCT03842696 | Hematologic Dis... Acute Leukemia ... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Myelodysplastic... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non Hodgkin Lym... Graft Vs Host D... Graft-versus-ho... | Vorinostat Blood and Marro... Tacrolimus (or ... Methotrexate Mycophenolate M... Cyclophosphamid... | 3 Years - 39 Years | University of Michigan Rogel Cancer Center | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| Cardiac Coherence Combined With Personal Physical Activity in Patients With Cancer | NCT03356171 | Physical Activi... Cancer Hematologic Dis... | Cardiac Coheren... Adapted Physica... | 18 Years - | Centre Hospitalier Universitaire de la Réunion | |
| RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL | NCT05902845 | Neoplasms Hematologic Neo... Hematologic Dis... | RD13-02 cell in... | 3 Years - 70 Years | Anhui Provincial Hospital | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics | NCT04209829 | Hematologic Dis... | 15 Years - | Assistance Publique - Hôpitaux de Paris | ||
| Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML | NCT01191801 | Acute Myeloid L... | vosaroxin + cyt... placebo + cytar... | 18 Years - | Sunesis Pharmaceuticals | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach | NCT03540654 | Hematologic Dis... Chronic Myeloid... | Budget impact | 18 Years - | University Hospital, Bordeaux | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia | NCT01998828 | Polycythemia Ve... Essential Throm... | Momelotinib | 18 Years - | Sierra Oncology LLC - a GSK company | |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | NCT03165734 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Physician's Cho... | 18 Years - | CTI BioPharma | |
| A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India | NCT05891249 | Anemia | Luspatercept | 18 Years - | Bristol-Myers Squibb | |
| Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT | NCT01220297 | Hematologic Dis... Acute-graft-ver... Leukemia Non-Hodgkin Lym... Hodgkin Lymphom... | Sirolimus Mycophenolate m... Carmustine Etoposide Cyclophosphamid... FTBI | 2 Years - 60 Years | Stanford University | |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT | NCT00350181 | Leukemia Lymphoma, Non-H... Hematologic Dis... Acute GVHD | Sirolimus MMF BCNU VP-16 CY FTBI BU | 2 Years - 60 Years | Stanford University | |
| Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia | NCT00607997 | Leukemia Acute Disease Acute Myeloid L... Nonlymphocytic ... Myelodysplastic... | vosaroxin | 60 Years - | Sunesis Pharmaceuticals | |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | NCT01716806 | Hodgkin Disease Peripheral T Ce... | brentuximab ved... bendamustine dacarbazine nivolumab | 18 Years - | Seagen Inc. | |
| Oligosaccharide for Cdiff(+) Heme-onc Patients | NCT03778606 | Clostridium Dif... Hematologic Dis... | Potato starch | 18 Years - | Medical College of Wisconsin | |
| Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation | NCT03159702 | Hematological M... Multiple Myelom... | Evomela Fludarabine Total Body Irra... | 18 Years - | Medical College of Wisconsin | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | NCT02292446 | Polycythemia Ve... | Ruxolitinib | 18 Years - | Novartis | |
| Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide | NCT00800839 | Hematologic Dis... Leukemia Lymphoma Myeloma | Busulfan Fludarabine Cyclophosphamid... | 6 Months - 75 Years | M.D. Anderson Cancer Center | |
| A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) | NCT00502112 | Myelodysplastic... | lintuzumab lenalidomide | 18 Years - | Seagen Inc. | |
| Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) | NCT01201811 | Myelodysplastic... | Azacitidine | 18 Years - | Celgene | |
| PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients | NCT04243434 | Hematologic Dis... | Vincristine Sul... CHOP R-CHOP | 18 Years - | Acrotech Biopharma Inc. | |
| Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | NCT01026415 | Carcinomas Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... Neoplasms | brentuximab ved... rifampin midazolam ketoconazole brentuximab ved... | 18 Years - | Seagen Inc. | |
| Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses | NCT02467270 | Myeloid Leukemi... | Ponatinib | 18 Years - | Takeda | |
| Allogeneic Cell Therapy for Adults With Hematologic Malignancies | NCT00208962 | Hematologic Dis... | chemotherapy an... | 18 Years - | Emory University | |
| Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients | NCT02108444 | Hepatitis Hepatitis B Lymphoma Hematologic Dis... | 18 Years - 80 Years | Peking University | ||
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | NCT01511289 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Philadelphia Ch... Bone Marrow Dis... Hematologic Dis... | Imatinib Radotinib | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) | NCT02252159 | MPN (Myeloproli... | 18 Years - | Incyte Corporation | ||
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma | NCT00435916 | Lymphoma, Large... Lymphoma, Non-H... | SGN-40 | 18 Years - | Seagen Inc. | |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File. | NCT03868527 | Hematologic Dis... | Data collection | 16 Years - | Hospices Civils de Lyon | |
| CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases | NCT05827835 | Hematologic Dis... Neoplasms | CD7 CAR-T cells... Allogeneic hema... | 18 Years - 75 Years | Zhejiang University | |
| Trial to Reduce Alloimmunization to Platelets (TRAP) | NCT00000589 | Blood Platelets Hematologic Dis... Immunization Leukemia, Myelo... Blood Transfusi... | platelet transf... | 15 Years - 75 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL | NCT00655837 | Lymphoma, Large... Lymphoma, Non-H... | SGN-40 rituximab gemcitabine | 18 Years - | Seagen Inc. | |
| Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors | NCT04450927 | Wide Spectrum o... Hematologic Dis... | 2 Years - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) | NCT01100502 | Disease, Hodgki... | brentuximab ved... placebo | 18 Years - | Seagen Inc. | |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | NCT06001385 | Acute Lymphobla... Acute Myeloid L... Acute Leukemia Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Lymphoma Chronic Myelomo... Pro-Lymphocytic... Myelofibrosis | Busulfan Fludarabine PBSC Hematopoie... Post-Transplant... Mesna Tacrolimus Mycophenolate M... Patient Reporte... Melphalan Total-body irra... Cyclophosphamid... | 18 Years - | Center for International Blood and Marrow Transplant Research | |
| A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | NCT05147493 | Multiple Myelom... Renal Impairmen... Neoplasms, Plas... Neoplasms by Hi... Neoplasms Paraproteinemia... Blood Protein D... Hematologic Dis... | Isatuximab Bortezomib Cyclophosphamid... Dexamethasone Lenalidomide | 18 Years - | Hellenic Society of Hematology | |
| A Safety Study in Patients With Chronic Lymphocytic Leukemia | NCT00283101 | Leukemia, Lymph... | SGN-40 (anti-hu... | 18 Years - | Seagen Inc. | |
| Digital Therapeutic for Adolescent Depressive Symptoms in Hematology, Oncology, and Weight Management | NCT05351866 | Depression Depressive Diso... Depressive Symp... Depressive Epis... Adolescent Beha... Adolescent - Em... Hematologic Dis... Oncology Weight, Body | CBT-based mobil... Mobile control ... | 13 Years - 22 Years | Limbix Health, Inc. | |
| A Safety Study in Patients With Chronic Lymphocytic Leukemia | NCT00283101 | Leukemia, Lymph... | SGN-40 (anti-hu... | 18 Years - | Seagen Inc. | |
| A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma | NCT00848926 | Disease, Hodgki... | brentuximab ved... | 12 Years - | Seagen Inc. | |
| Systematic and Mechanism-based Approach to Rational Treatment Trials of Blood Cancer | NCT03488641 | Hematologic Dis... Treatment | ex-vivo drug re... | 18 Years - | German Cancer Research Center | |
| Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | NCT01183949 | Multiple Myelom... | AT7519M Bortezomib | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma | NCT02155634 | Multiple Myelom... Neoplasms Plasma Cells Paraproteinemia... Blood Protein D... Hematologic Dis... Therapeutic Use... | Lenalidomide | 18 Years - | Celgene | |
| WB-EMS and Nutrition in Patients With Hematological Malignancies | NCT03556748 | Hematologic Dis... Cachexia; Cance... Leukemia Myeloma Lymphoma Cancer | whole-body elec... | 18 Years - | University of Erlangen-Nürnberg Medical School | |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03578367 | CML Chronic Myeloge... Leukemia, Myelo... Hematologic Dis... | Asciminib add-o... Imatinib Nilotinib Asciminib singl... | 18 Years - | Novartis | |
| Muscle Dysfunction in Patients With Haematological Diseases | NCT05150561 | Hematologic Dis... Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Lymphoma | 18 Years - | Rigshospitalet, Denmark | ||
| Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF | NCT01423851 | Primary Myelofi... Post-Polycythem... Post-Essential ... | NS-018 | 18 Years - | NS Pharma, Inc. | |
| Oligosaccharide for Cdiff(+) Heme-onc Patients | NCT03778606 | Clostridium Dif... Hematologic Dis... | Potato starch | 18 Years - | Medical College of Wisconsin | |
| Registry of Philadelphia-Negative Myeloproliferative Neoplasms | NCT02380378 | Hematologic Dis... | 18 Years - | Hospital Israelita Albert Einstein | ||
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | NCT01787552 | Primary Myelofi... Thrombocytosis Essential Throm... Polycythemia Ve... Myeloproliferat... Bone Marrow Dis... Hematologic Dis... Blood Coagulati... Blood Platelet ... Hemorrhagic Dis... | LDE225 INC424 | 18 Years - | Novartis | |
| A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM | NCT04786028 | Multiple Myelom... | Isatuximab | 18 Years - | Canadian Myeloma Research Group | |
| Cord Blood Stem Cell Transplantation Study (COBLT) | NCT00000603 | Anemia, Aplasti... Fanconi Anemia Hematologic Dis... Leukemia Neoplasms Severe Combined... Hematopoietic S... Myelodysplastic... | stem cell trans... | - 55 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) | NCT05641324 | Multiple Myelom... Relapsed Cancer Refractory Mult... Adult Disease Hematologic Dis... | ANV419 Lenalidomide wi... Daratumumab | 18 Years - | Anaveon AG | |
| A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) | NCT04173494 | Primary Myelofi... Post-polycythem... Post-essential ... | Momelotinib Placebo to matc... Danazol Placebo to matc... | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. | NCT01844765 | Philadelphia Po... | nilotinib | 1 Year - 17 Years | Novartis | |
| Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies | NCT05895994 | Neoplasms Hematologic Neo... Neoplasms by Si... Hematologic Dis... | RD13-02 cell in... | 3 Years - 70 Years | Wuhan Union Hospital, China | |
| Impact of Early Implementation of Narrative Medicine Techniques on Patient Centered Attitudes of Medical Students | NCT03041571 | Narrative Medic... Chronic Disease Terminal Illnes... Cancer Diabetes Mellit... Cystic Fibrosis Rheumatologic D... Oncologic Disor... Hematologic Dis... | Patient Provide... Interview perfo... | 8 Years - 100 Years | University of Florida | |
| SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes. | NCT00113893 | Bone Marrow Dis... Myelodysplastic... Hematologic Dis... Bone Marrow Neo... | SCIO-469 SCIO-469 SCIO-469 SCIO-469 | 18 Years - | Scios, Inc. | |
| Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics | NCT04209829 | Hematologic Dis... | 15 Years - | Assistance Publique - Hôpitaux de Paris | ||
| Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") | NCT04474678 | Brain Tumor Neurofibromatos... Sarcoma Leukemia Hematologic Dis... Neuroblastoma | "My Logbook! - ... | 6 Years - 14 Years | Medical University of Vienna | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| Myeloproliferative Neoplasms (MPNs) Patient Registry | NCT02760238 | Primary Myelofi... Polycythemia Ve... Essential Throm... Mastocytosis Leukemia, Myelo... Leukemia, Myelo... Chronic Eosinop... Myelodysplastic... Neoplasms Leukemia, Myelo... | Observational | - | University Health Network, Toronto | |
| Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. | NCT02038036 | Polycythemia Ve... | Best Available ... Ruxolitinib | 18 Years - | Novartis | |
| A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma | NCT01063907 | Multiple Myelom... | KW-2478 Bortezomib | 18 Years - | Kyowa Kirin Co., Ltd. | |
| Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | NCT02786485 | Leukemia Myelodysplastic... Lymphomas Multiple Myelom... Other High-risk... | rivogenlecleuce... Rimiducid | 18 Years - 65 Years | Bellicum Pharmaceuticals | |
| A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | NCT05298683 | Multiple Myelom... Renal Impairmen... Neoplasms, Plas... Neoplasms by Hi... Neoplasms Paraproteinemia... Blood Protein D... Hematologic Dis... | Isatuximab Pomalidomide Dexamethasone Acetaminophen (... Ranitidine (or ... Diphenhydramine... | 18 Years - | Hellenic Society of Hematology | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | NCT01421667 | Lymphoma, B-Cel... Lymphoma, Large... Lymphoma, Non-H... Lymphoma, T-Cel... | brentuximab ved... rituximab | 6 Years - | Seagen Inc. | |
| A Safety Study in Patients With Chronic Lymphocytic Leukemia | NCT00283101 | Leukemia, Lymph... | SGN-40 (anti-hu... | 18 Years - | Seagen Inc. | |
| A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India | NCT05891249 | Anemia | Luspatercept | 18 Years - | Bristol-Myers Squibb |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
